Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

1.

Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit.

Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM.

Mol Cell Biol. 1998 Mar;18(3):1379-87.

PMID:
9488453
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Synergistic activation of a family of phosphoinositide 3-kinase via G-protein coupled and tyrosine kinase-related receptors.

Katada T, Kurosu H, Okada T, Suzuki T, Tsujimoto N, Takasuga S, Kontani K, Hazeki O, Ui M.

Chem Phys Lipids. 1999 Apr;98(1-2):79-86. Review.

PMID:
10358930
[PubMed - indexed for MEDLINE]
3.

Structure and function of phosphatidylinositol-3,4 kinase.

Funaki M, Katagiri H, Inukai K, Kikuchi M, Asano T.

Cell Signal. 2000 Mar;12(3):135-42. Review.

PMID:
10704820
[PubMed - indexed for MEDLINE]
4.

Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits?

Geering B, Cutillas PR, Vanhaesebroeck B.

Biochem Soc Trans. 2007 Apr;35(Pt 2):199-203. Review.

PMID:
17371237
[PubMed - indexed for MEDLINE]
5.

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.

Huang CH, Mandelker D, Gabelli SB, Amzel LM.

Cell Cycle. 2008 May 1;7(9):1151-6. Epub 2008 Feb 27. Review.

PMID:
18418043
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The regulation of class IA PI 3-kinases by inter-subunit interactions.

Backer JM.

Curr Top Microbiol Immunol. 2010;346:87-114. doi: 10.1007/82_2010_52. Review.

PMID:
20544340
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Class I PI3K in oncogenic cellular transformation.

Zhao L, Vogt PK.

Oncogene. 2008 Sep 18;27(41):5486-96. doi: 10.1038/onc.2008.244. Review.

PMID:
18794883
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Phosphatidylinositol 3-kinase: the oncoprotein.

Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A.

Curr Top Microbiol Immunol. 2010;347:79-104. doi: 10.1007/82_2010_80. Review.

PMID:
20582532
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.

Hao Y, Zhao S, Wang Z.

Toxicol Pathol. 2014 Jan;42(1):140-7. doi: 10.1177/0192623313506794. Epub 2013 Oct 31. Review.

PMID:
24178578
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The structural basis of PI3K cancer mutations: from mechanism to therapy.

Liu S, Knapp S, Ahmed AA.

Cancer Res. 2014 Feb 1;74(3):641-6. doi: 10.1158/0008-5472.CAN-13-2319. Epub 2014 Jan 23. Review.

PMID:
24459181
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Structural effects of oncogenic PI3Kα mutations.

Gabelli SB, Huang CH, Mandelker D, Schmidt-Kittler O, Vogelstein B, Amzel LM.

Curr Top Microbiol Immunol. 2010;347:43-53. doi: 10.1007/82_2010_53. Review.

PMID:
20593314
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk